KingMed Diagnostics

KingMed Diagnostics (金域医学), formally Guangzhou KingMed Diagnostics Group Co., Ltd., is a Chinese independent clinical laboratory (ICL) company headquartered in Guangzhou, Guangdong. It was established in the early 2000s as one of the first private third-party medical testing providers in China, at a time when hospital laboratories handled almost all diagnostic testing in-house. KingMed built a network of regional central laboratories that collect samples from hospitals, clinics and community health institutions and return standardized test results, allowing smaller healthcare providers to access tests they could not economically run themselves. The company's service portfolio spans clinical chemistry, immunology, hematology, microbiology, molecular diagnostics, pathology and genetics, including specialized and esoteric testing such as genetic sequencing, prenatal screening and oncology-related assays. KingMed serves thousands of hospitals and healthcare institutions across China through a nationwide logistics and laboratory network, and it has expanded into areas such as pathology consultation, clinical trial laboratory services and health screening. KingMed is listed on the Shanghai Stock Exchange under the ticker 603882, having completed an initial public offering in 2017. The company is one of the largest independent laboratory operators in China alongside peers such as Dian Diagnostics and ADICON Holdings, and it benefited strongly from China's growing demand for diagnostic testing, chronic disease management and precision medicine. Its brand is associated with scale, standardized quality management and broad test menus rather than consumer-facing products. Note: the supplied evidence snippets concern unrelated subjects (a Bollywood actor's YouTube channel and a Roche diabetes campaign) and contain no information about KingMed; the dossier above relies on well-established public facts about the company and should be verified against primary sources.

KingMed Diagnostics emerged in the early 2000s as part of a first wave of private third-party medical laboratories in China. At the time, Chinese hospitals performed nearly all diagnostic testing in their own laboratories, and independent commercial labs were a novel model. KingMed's approach was to build centralized, high-throughput regional laboratories that could serve many hospitals at once, using logistics networks to move samples from client institutions to the lab and results back again. This model lowered costs per test and gave smaller hospitals access to specialized assays. Through the 2000s and 2010s the company expanded its laboratory footprint across provinces, adding test menus in molecular diagnostics, genetics and pathology. Growth was supported by China's healthcare reforms, which encouraged the separation of testing from treatment and the outsourcing of laboratory services, as well as by rising demand for chronic disease monitoring, cancer diagnostics and precision medicine. A major turning point came in 2017, when Guangzhou KingMed Diagnostics Group Co., Ltd. completed an initial public offering and listed on the Shanghai Stock Exchange under the ticker 603882, giving it capital to expand its laboratory network and invest in advanced testing technologies. In the years that followed, KingMed continued to broaden its specialized testing portfolio, develop pathology consultation and remote diagnostic services, and build capabilities in clinical trial laboratory services and genomic testing. During the COVID-19 pandemic, KingMed was among the Chinese laboratory operators that provided large-scale nucleic acid testing capacity, which significantly raised its public profile and revenue. In the post-pandemic period the company has focused on high-value esoteric testing, digitalization of laboratory workflows and expanding services to grassroots healthcare institutions. It remains one of the largest independent clinical laboratory groups in China, competing with peers such as Dian Diagnostics and ADICON Holdings. Note: the supplied evidence does not cover KingMed; this history is based on well-established public information and should be verified against primary sources.

• 2020

  Provided large-scale nucleic acid testing capacity during the COVID-19 pandemic.

• 2017

  Completed IPO and listed on the Shanghai Stock Exchange under ticker 603882.

• 2003

  KingMed Diagnostics founded in Guangzhou as a private third-party clinical laboratory.

Scale-driven independent clinical laboratory platform serving hospitals and healthcare institutions across China with standardized, broad-menu diagnostic testing.

• Clinical chemistry and immunology panels

• Molecular diagnostics and genetic sequencing

• Anatomic pathology and remote pathology consultation

• Prenatal screening and reproductive genetics

• Clinical trial laboratory services

• 2026-10-10

  KingMed Diagnostics and First Affiliated Hospital of Guangzhou Medical University jointly release lung cancer pathology-gene AI model DeepGEM 2.0[3]金域医学与广州医科大学附属第一医院联合发布肺癌病理基因大模型DeepGEM 2.0163.com

  Reported: 2026-10-10

  On October 10, 2026, at the AI-empowered lung cancer precision diagnosis and treatment summit forum in Guangzhou, KingMed Diagnostics (金域医学, 603882) and the First Affiliated Hospital of Guangzhou Medical University officially released DeepGEM 2.0, a multimodal pathology-gene large model for lung cancer, and simultaneously launched a multi-center research project involving 50 medical institutions nationwide, marking the model's move into large-scale clinical application validation. The upgraded model covers 12 genes corresponding to domestically approved lung cancer targeted therapies, can output results in as fast as one minute, is planned for lightweight deployment in over 500 medical institutions, and is expected to lower lung cancer gene testing costs to a few hundred yuan.

1. 1KingMed Diagnostics official websitekingmed.com.cn
2. 2Shanghai Stock Exchange listing information (603882)sse.com.cn
3. 3金域医学与广州医科大学附属第一医院联合发布肺癌病理基因大模型DeepGEM 2.0163.com